Evidence map›Paper›PMID 40445524›Full record

ArticleInternational journal of clinical oncology2025

Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.

Margaret Shatara, Nicole M Brossier, Andrew Cluster, Ali Y Mian, Sonika Dahiya, Amy E Armstrong, Angela C Hirbe, David H Gutmann, Kenneth Aldape, Mohamed S Abdelbaki

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Margaret ShataraPediatric Neuro-Oncology Program, Department of Pediatric Hematology and Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, 55404, USA. Margaret.shatara@childrensmn.org.ORCID http://orcid.org/0000-0001-5821-6216
Nicole M BrossierDepartment of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO, USA.
Andrew ClusterDepartment of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO, USA.
Ali Y MianDepartment of Pathology and Immunology, Washington University, St. Louis, MO, USA.
Sonika DahiyaMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Amy E ArmstrongDepartment of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO, USA.
Angela C HirbeDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
David H GutmannDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mohamed S AbdelbakiDepartment of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCentral nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.

methodsThe tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.

resultsFrom January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).

conclusionThis initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.

Indexed as

Central Nervous System NeoplasmsMedical OncologyAdolescentChildChild, PreschoolCross-Sectional StudiesFemaleHumansMalePediatricsRetrospective StudiesCNS tumorsGlobal health disparitiesInternational collaborationPediatric neuro-oncologyTelemedicine

Identifiers

PMID40445524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.